People

Charles Carignan Selected as Anaconda Biomed Board Chairman

New chairman has served on FDA, WHO, CMS, and UN committees.

By: Michael Barbella

Managing Editor

Anaconda Biomed S.L. has named veteran medtech executive Charles (Chuck) Carignan, M.D., as board chairman.

“It is a privilege to welcome Chuck to Anaconda Biomed,” Anaconda Biomed CEO Trent Reutiman said. “With his leadership experience at Boston Scientific, numerous private venture-backed startups, and international government health agencies, Chuck brings a proven track record of developing and overseeing global healthcare companies. His operational and clinical insights will be invaluable as we continue to grow.”

Dr. Carignan has extensive clinical, product development, commercialization, and leadership expertise, having served on committees of the U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, the World Health Organization, the United Nations, and the U.S. Agency for International Development.

Additionally, Dr. Carignan has led multiple successful corporations: he was the founding president and CEO of NinePoint Medical, president and CEO of BionX Medical, and CEO of SoniVie Inc. Additional prior roles include executive vice president and chief medical officer at Novasys Medical, chief medical officer of Endosurgery at Boston Scientific, and vice president of clinical research and medical affairs at Conceptus Inc. He currently serves as the executive chairman of Cairdac, chairman of SamanTree Medical, and a director of Biothea and Prothea.

Dr. Carignan is joining the company at a critical time as enrollment progresses in the global investigational device exemption (IDE) ATHENA clinical trial, and additional work continues on building the company’s product pipeline.

“Beginning with the ANA Funnel Catheter technology, Anaconda has the opportunity to literally change the shape of the mechanical thrombectomy field,” Dr. Carignan stated. “I am honored to join the board to actively contribute to the next phase of the company’s successes by working closely with Trent and the rest of the board.”

ANA5 Advanced Neurovascular Access (ANA Funnel Catheter) is designed as an expandable and collapsable funnel catheter for interventional neurovascular procedures requiring clot retrieval, and benefiting from limiting flow and/or flow reversal towards that goal. The device consists of a radiopaque nitinol braid funnel, covered with a polymeric coating enabling local flow arrest. The catheter is currently an investigational device and is not available for sale in the United States or the European Union.

Anaconda Biomed is developing next-generation thrombectomy systems for treating ischemic stroke. At the heart of its product portfolio is the ANA Funnel Catheter. Anaconda Biomed has received funding from prominent life science investment firms, including Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell, and private investors. Additionally, through public grants, the company has received significant public support from ENISA, CDTI (Innvierte and NEOTEC), the Ministry of Science & Innovation (Emplea and Retos), EIB, and EIT Health.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters